Table 2. Univariate and multivariate survival analyses of OS and DFS in CRC patients of FUSCC.
| OS | DFS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | P | Multivariate analysis | P | Univariate analysis | P | Multivariate analysis | P | |
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
| Age (years) | 0.071 | 0.292 | ||||||
| ≤60 | 1.000 | 1.000 | ||||||
| >60 | 1.380 (0.973–1.957) | 1.154 (0.884–1.508) | ||||||
| Gender | 0.251 | 0.524 | ||||||
| Male | 1.000 | 1.000 | ||||||
| Female | 1.289 (0.835–1.987) | 0.907 (0.672–1.225) | ||||||
| Tumor location | 0.071 | 0.032 | 0.414 | |||||
| Colon | 1.000 | 1.000 | 1.000 | |||||
| Rectum | 0.725 (0.512–1.027) | 0.745 (0.570–0.974) | 1.165 (0.807–1.682) | |||||
| Tumor length (cm) | 0.002 | 0.250 | 0.012 | 0.952 | ||||
| ≤3 cm | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| >3 cm | 1.918 (1.260–2.917) | 1.296 (0.833–2.018) | 1.468 (1.086–1.984) | 1.010 (0.732–1.394) | ||||
| T stage | <0.001 | <0.001 | <0.001 | <0.001 | ||||
| T1 | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| T2 | 1.445 (0.398–5.251) | 1.046 (0.284–3.847) | 1.913 (0.721–5.073) | 1.591 (0.593–4.268) | ||||
| T3 | 2.812 (0.876–9.023) | 0.930 (0.274–3.155) | 3.344 (1.360–8.222) | 1.655 (0.645–4.245) | ||||
| T4 | 7.995 (2.513–25.442) | 2.280 (0.674–7.714) | 7.685 (3.125–18.898) | 3.773 (1.426–9.984) | ||||
| N stage | <0.001 | <0.001 | <0.001 | <0.001 | ||||
| N0 | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| N1 | 2.464 (1.581–3.841) | 1.794 (1.104–2.915) | 1.965 (1.366–2.826) | 1.309 (0.905–1.892) | ||||
| N2 | 5.149 (3.379–7.846) | 2.946 (1.725–5.031) | 4.831 (3.456–6.754) | 2.266 (1.497–3.428) | ||||
| Differentiation | 0.011 | 0.641 | <0.001 | 0.962 | ||||
| Well/Moderate | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| Poor | 1.778 (1.221–2.589) | 0.864 (0.572–1.306) | 1.674 (1.253–2.236) | 1.029 (0.753–1.407) | ||||
| Unknown | 1.193 (0.550–2.587) | 1.217 (0.550–2.694) | 0.892 (0.455–1.752) | 0.940 (0.473–1.869) | ||||
| Venous invasion | <0.001 | 0.589 | <0.001 | 0.222 | ||||
| Negative | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| Positive | 3.312 (2.336–4.697) | 1.133 (0.720–1.783) | 2.841 (2.163–3.730) | 1.249 (0.875–1.783) | ||||
| <0.001 | 0.277 | <0.001 | 0.058 | |||||
| Negative | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| Positive | 2.488 (1.722–3.594) | 1.256 (0.833–1.892) | 2.374 (1.779–3.169) | 1.361 (0.990–1.870) | ||||
| CEA (ng/mL) | <0.001 | 0.034 | <0.001 | 0.017 | ||||
| Normal (0–5.2) | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| High (>5.2) | 3.308 (2.294–4.768) | 1.565 (1.035–2.368) | 2.448 (1.868–3.209) | 1.456 (1.071–1.980) | ||||
| CA199 (U/mL) | <0.001 | 0.458 | <0.001 | 0.399 | ||||
| Normal (0–27) | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| High (>27) | 3.241 (2.287–4.593) | 1.220 (0.721–2.065) | 1.943 (1.466–2.575) | 0.838 (0.556–1.263) | ||||
| CA50 (IU/mL) | <0.001 | 0.010 | <0.001 | 0.020 | ||||
| Normal (0–25) | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| High (>25) | 5.288 (3.533–7.914) | 1.905 (1.168–3.106) | 3.322 (2.326–4.746) | 1.647 (1.080–2.510) | ||||
| CA125 (U/mL) | <0.001 | 0.144 | <0.001 | 0.212 | ||||
| Normal (0–35) | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| High (>35) | 3.410 (2.115–5.500) | 1.491 (0.873–2.549) | 2.329 (1.523–3.563) | 1.337 (0.847–2.112) | ||||
| CA242 | <0.001 | 0.683 | <0.001 | 0.397 | ||||
| Normal (0–25) | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| High (>35) | 2.746 (1.938–3.892) | 1.109 (0.676–1.819) | 1.988 (1.511–2.615) | 1.177 (0.807–1.718) | ||||
| CA724 (U/mL) | <0.001 | <0.001 | <0.001 | 0.001 | ||||
| Normal (0–20) | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| High (>20) | 3.467 (2.429–4.947) | 2.515 (1.688–3.748) | 2.330 (1.713–3.169) | 1.723 (1.246–2.381) | ||||